AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed…
Bayer and Recursion focus research collaboration on Oncology Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have…
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Takeda (TSE:4502/NYSE:TAK) today…
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients,…
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics,…
BioPhy Launches Breakthrough AI Platform to Accelerate the Trillion Dollar Drug Development Market BioPhy today launched its AI operating system that radically accelerates the identification and development of the most…
Marinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY® (ganaxolona) –Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), uma empresa farmacêutica especializada no desenvolvimento de terapêuticas inovadoras para tratar…
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023 Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST…
Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 Gilead Sciences, Inc. (Nasdaq: GILD) and Kite,…
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc.…
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat…